Sorafenib in Recurrent and/or Metastatic Salivary Gland Carcinomas: Phase II Study

Trial Profile

Sorafenib in Recurrent and/or Metastatic Salivary Gland Carcinomas: Phase II Study

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2016

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Salivary gland cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Nov 2016 Status changed from active, no longer recruiting to completed as reported by results published in the European Journal of Cancer
    • 04 Nov 2016 Results assessig safety and efficacy published in the European Journal of Cancer
    • 05 Oct 2013 New source identified and integrated (European Clinical Trials Database; EudraCT2010-020375-24).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top